KRAS activating mutations are detected in 25% to 30% of non-squamous non-small cell lung cancers, representing the most common genetic driver event in this cancer type. The Ras protein family includes three subtypes—KRAS, HRAS, and NRAS—with KRAS mutations accounting for 85% of Ras-driven cancers. KRAS mutations are most prevalent in pancreatic, colorectal, and lung cancers, with the KRAS G12C single nucleotide variant being the most common in non-small cell lung cancer, occurring in approximately 13% of lung adenocarcinomas. KRAS-mutant non-small cell lung cancers constitute a molecularly diverse and clinically heterogeneous group, for which standard treatment regimens offer limited clinical benefit. The KRAS protein's lack of well-defined binding pockets and allosteric sites, coupled with its extremely high affinity for GTP, has made traditional pharmacological strategies ineffective in identifying direct target drugs. As a result, KRAS mutations have long been considered "undruggable."
The notion of KRAS G12C being "undruggable" persisted for nearly four decades until several groundbreaking structural and mechanistic studies laid the foundation for the clinical development of covalent and selective KRAS G12C inhibitors. In 2013, researchers identified an allosteric binding pocket behind the switch-II region of the KRAS G12C protein. Using the structure of KRAS G12C, they established a disulfide fragment screening model and identified compounds that bind to the switch-II pocket, paving the way for further research. In 2014, researchers proposed the first KRAS G12C inhibitor molecule, which reduced pERK and pAkt levels without affecting wild-type KRAS. Subsequent studies developed covalent KRAS G12C inhibitors that interact exclusively with the GDP-bound state of KRAS G12C. However, due to poor plasma stability, these inhibitors did not advance to further research. The TR-FRET KRAS G12C/CRBN PROTAC assay kit enables quantitative detection of the dual-binding activity of PROTAC molecules with KRAS G12C and CRBN, providing a technical tool for degrader screening.
PROTAC molecules consist of three components: a target protein ligand, an E3 ligase ligand, and a linker chain. These molecules simultaneously bind to the target protein and E3 ligase, inducing ubiquitination and proteasomal degradation of the target protein. Compared to traditional inhibition strategies, PROTAC technology offers advantages such as targeting traditionally "undruggable" proteins, a catalytic mechanism of action, and sustained inhibitory effects. As KRAS G12C presents challenges for traditional small-molecule inhibitor development, the PROTAC strategy provides a new approach for targeting it. CRBN-based KRAS G12C PROTAC molecules, by simultaneously binding KRAS G12C and CRBN, induce the degradation of KRAS G12C, completely blocking its signaling function. TR-FRET technology can be applied to study the synergistic binding of PROTAC molecules with KRAS G12C and CRBN, assessing their potential to induce target protein degradation.
TR-FRET technology combines the principles of time-resolved fluorescence and fluorescence resonance energy transfer. Time-resolved fluorescence leverages the long-lived fluorescence properties of lanthanide chelates to effectively eliminate interference from short-lived background fluorescence. Fluorescence resonance energy transfer occurs when donor and acceptor fluorophores are sufficiently close, generating specific signals through non-radiative energy transfer. In the KRAS G12C/CRBN PROTAC assay kit, donor fluorophore-labeled KRAS G12C protein and acceptor fluorophore-labeled CRBN protein are co-incubated. When a PROTAC molecule simultaneously binds both, the donor and acceptor are brought into proximity, enabling energy transfer. The addition of competitive compounds or degraders reduces signal intensity, reflecting the compound's ability to block PROTAC-mediated binding. This assay is homogeneous, wash-free, highly sensitive, and high-throughput.
The TR-FRET KRAS G12C/CRBN PROTAC assay kit offers multifaceted value in the development of protein-degrading drugs targeting KRAS G12C. During PROTAC molecule design, it can validate whether the linkage strategy between KRAS G12C and CRBN ligands is effective and evaluate the impact of linker length and attachment sites on dual-binding capability. In structural optimization, it enables quantitative comparison of the binding affinity and synergistic effects of different PROTAC molecules, providing data to support structure-activity relationship studies. During compound screening, it facilitates high-throughput assessment of whether molecules in a compound library with KRAS G12C-binding activity can also bind CRBN, rapidly identifying lead compounds with degradation potential. The high-throughput nature of TR-FRET technology accelerates the discovery of PROTAC drugs.
A series of ongoing clinical trials are evaluating the efficacy of KRAS G12C inhibitors. Research has revealed that certain KRAS receptor tyrosine kinases can trigger nucleotide exchange, with AURK signaling promoting effector activation and cell cycle progression. Cells with KRAS G12C mutations can rapidly escape inhibition and resume proliferation, transitioning into a drug-insensitive active state. This finding suggests that inhibiting KRAS G12C activity alone may be insufficient to fully control tumor growth, and PROTAC-mediated KRAS G12C degradation may represent a more effective strategy. The TR-FRET KRAS G12C/CRBN PROTAC assay kit can assess the activity of KRAS G12C degraders, validate their mechanisms of action, and offer new solutions to overcome drug resistance.
Nanjing UA-Bio Technology Co., Ltd. has independently developed the "UniOne® TR-FRET Human KRAS[G12C]/CRBN PROTAC Binding Kit (GDP/GTP load)" (Catalog No.: UA086001), a high-performance analytical platform specifically designed for studying PROTAC molecules that target the KRAS G12C mutant protein and induce its interaction with the CRBN (Cereblon) E3 ubiquitin ligase. This kit leverages time-resolved fluorescence resonance energy transfer (TR-FRET) technology and supports the evaluation of PROTAC-mediated ternary complex formation between KRAS G12C and CRBN under GDP- or GTP-loaded states. It provides a stable, reliable, and standardized solution for applications such as targeted protein degradation (PROTAC) technology development, antitumor drug screening, and mutation-specific degrader research.
| Core Advantages | Detailed Parameters / Functional Description |
|---|---|
| High Purity and Full Biological Activity | The kit's core components include highly purified, biologically active human KRAS G12C mutant protein (supporting GDP- or GTP-loaded states) and CRBN-DDB1 complex, validated through multi-dimensional quality control. The KRAS G12C protein maintains its correct native conformation and nucleotide-binding state, accurately simulating PROTAC-mediated ternary complex formation under physiological conditions. This ensures experimental accuracy, reproducibility, and functional relevance. |
| Flexible Nucleotide-Loading States | The kit provides GDP- and GTP-loaded conditions, allowing users to evaluate PROTAC-mediated degradation efficiency of KRAS G12C in its inactive (GDP-bound) or active (GTP-bound) states. This feature is critical for in-depth studies on conformation-dependent PROTAC degradation strategies for KRAS G12C mutants. |
| Exceptional Lot-to-Lot Consistency and Stability | Backed by an internationally leading protein expression platform, highly standardized production processes, and a rigorous quality control system, the kit delivers outstanding long-term stability and excellent lot-to-lot consistency. It provides a solid foundation for continuous PROTAC drug screening and mechanistic research. |
| Ready-to-Use Flexible Experimental Platform | The kit employs a homogeneous TR-FRET technology with a simple "add-mix-read" workflow, eliminating the need for cumbersome washing steps. Its optimized formulation is compatible with automated multi-well plate (96/384-well) platforms, making it suitable for high-throughput screening of KRAS G12C-targeting PROTAC molecules, nucleotide state-dependent degrader evaluation, ternary complex formation assays, and competitive binding experiments. |
Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or application inquiries regarding the "UniOne® TR-FRET Human KRAS[G12C]/CRBN PROTAC Binding Kit (GDP/GTP load)" (Catalog No.: UA086001), please feel free to contact us.
